Voyager Therapeutics Inc a biotech company focused on neurogenetic medicines announced the dosing of the first participants in its Phase a single ascending dose trial of VYTAU

Ocugen Inc a biotechnology company focused on developing novel gene and cell therapies as well as vaccines has announced the completion of dosing in the second cohort of its Phase GARDian clinical trial

Arexvy the worlds first respiratory syncytial virus vaccine has recently gained approval from the Health Sciences Authority of Singapore for immunizing individuals aged years and above against lower respiratory tract disease caused by RSV This groundbreaking achievement underscores GSKs commitment

Ractigen Therapeutics a leading clinicalstage pharmaceutical company dedicated to developing innovative therapies has announced a significant achievement the approval of its Investigational New Drug

Zai Lab Limited has announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted the supplemental Biologics License Application

Everest Medicines a biopharmaceutical company dedicated to advancing medicines and vaccines has announced the successful launch of NEFECON in China marking a significant advancement

Glenmark Pharmaceuticals Ltd has received final approval by the United States Food Drug Administration for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution Glenmarks Brimonidine Tartrate

Oragenics Inc a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders today announced an update on the company and its drug development program

Axonics Inc today announced that it has received regulatory approval from the Therapeutic Goods Administration for marketing the Axonics F rechargefree sacral neuromodulation system in Australia to treat adults with overactive bladder Approval of the Axonics rechargefree system

Reviva Pharmaceuticals Holdings Inc a latestage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system

EVQ Bio a whollyowned subsidiary of EVQ Nano today announced the successful completion of a PreInvestigational New Drug meeting with the US Food and Drug Administration

Nitrosamine Advance Workshop conducted on May th and th at Radisson Blu Mumbai International Airport has emerged as a watershed moment in the pharma industry boosting collaboration and innovation in the detection of the Nitrosamine landscape